Multicentre Real-world Experience of Upadacitinib in the Treatment of Crohn's Disease. Read more about Multicentre Real-world Experience of Upadacitinib in the Treatment of Crohn's Disease.
Inflammatory Bowel Disease in Patients with Congenital Chloride Diarrhoea. Read more about Inflammatory Bowel Disease in Patients with Congenital Chloride Diarrhoea.
Tofacitinib for Rescue Therapy in Acute Severe Ulcerative Colitis: A Real-world Experience. Read more about Tofacitinib for Rescue Therapy in Acute Severe Ulcerative Colitis: A Real-world Experience.
Long-term Outcomes of Paediatric Patients Admitted With Acute Severe Colitis- A Multicentre Study From the Paediatric IBD Porto Group of ESPGHAN. Read more about Long-term Outcomes of Paediatric Patients Admitted With Acute Severe Colitis- A Multicentre Study From the Paediatric IBD Porto Group of ESPGHAN.
Utility of DNA Flow Cytometric Analysis of Paraffin-embedded Tissue in the Risk Stratification and Management of 'Indefinite for dysplasia' in Patients With Inflammatory Bowel Disease. Read more about Utility of DNA Flow Cytometric Analysis of Paraffin-embedded Tissue in the Risk Stratification and Management of 'Indefinite for dysplasia' in Patients With Inflammatory Bowel Disease.
Corrigendum: Vedolizumab in Paediatric Inflammatory Bowel Disease: A Retrospective Multi-Centre Experience From the Paediatric IBD Porto Group of ESPGHAN. Read more about Corrigendum: Vedolizumab in Paediatric Inflammatory Bowel Disease: A Retrospective Multi-Centre Experience From the Paediatric IBD Porto Group of ESPGHAN.
Vedolizumab in Paediatric Inflammatory Bowel Disease: A Retrospective Multi-Centre Experience From the Paediatric IBD Porto Group of ESPGHAN. Read more about Vedolizumab in Paediatric Inflammatory Bowel Disease: A Retrospective Multi-Centre Experience From the Paediatric IBD Porto Group of ESPGHAN.
Phenotypic and Genotypic Characterisation of Inflammatory Bowel Disease Presenting Before the Age of 2 years. Read more about Phenotypic and Genotypic Characterisation of Inflammatory Bowel Disease Presenting Before the Age of 2 years.
The use of sirolimus (rapamycin) in the management of refractory inflammatory bowel disease in children. Read more about The use of sirolimus (rapamycin) in the management of refractory inflammatory bowel disease in children.
